Health Trials

Clinical trials

5

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

This is a Phase 2b study to evaluate the efficacy and safety of Imeroprubart in adults with CIDP.

Participants needed: 162
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Immunovant Sciences GmbHUpdated: Aug 21, 2026Locations: 141
Eligibility criteria

Have met clinical diagnostic criteria for typical CIDP or one of the following C... [+2]

Have current or prior history of IgM paraproteinemia with or without anti-myelin... [+11]

Read more
Status: Recruiting

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

This is a multi-center, global, randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.

Participants needed: 210
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Immunovant Sciences GmbHUpdated: Aug 12, 2026Locations: 160
Eligibility criteria

Participants with the ability to understand the requirements of the trial, provi... [+3]

Have previously been successfully treated with radioactive iodine (RAI) therapy... [+3]

Read more
Status: Recruiting

Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity

This is a Phase 2b, multicenter, randomized, double-blinded, placebo-controlled study to assess the efficacy and safety of IMVT-1402 in adult participants with moderate to severe systemic primary Sjogren's disease (SjD).

Participants needed: 180
Trial details
Phase: Phase 2Age: 18-74Biological sex: AllType: InterventionalSponsor: Immunovant Sciences GmbHUpdated: Aug 12, 2026Locations: 121
Eligibility criteria

Participants with a diagnosis of primary SjD for at least 12 months prior to the... [+3]

Participants with a diagnosis of secondary SjD, inadequately treated fibromyalgi... [+1]

Read more
Status: Recruiting

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment. The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine \[T3\] or free triiodothyronine \[FT3\]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26.

Participants needed: 240
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Immunovant Sciences GmbHUpdated: Aug 11, 2026Locations: 134
Eligibility criteria

Participants with the ability to understand the requirements of the trial, provi... [+3]

Have previously been successfully treated with radioactive iodine (RAI) therapy... [+3]

Read more
Status: Recruiting

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.

Participants needed: 231
Trial details
Phase: Phase 3Age: 18-80Biological sex: AllType: InterventionalSponsor: Immunovant Sciences GmbHUpdated: Jul 30, 2026Locations: 88
Eligibility criteria

Participants with the ability to understand the requirements of the trial, provi... [+2]

Have experienced myasthenic crisis within 12 weeks prior to the Screening Visit. [+2]

Read more